PPNAD Completed Phase 2 Trials for Osilodrostat (DB11837)

IndicationStatusPhase
DBCOND0075009 (PPNAD)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02468193Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeTreatment